Next Article in Journal
Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro
Previous Article in Journal
Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins
Previous Article in Special Issue
IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle

CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate

Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Author to whom correspondence should be addressed.
Cells 2019, 8(5), 456;
Received: 5 March 2019 / Revised: 10 May 2019 / Accepted: 11 May 2019 / Published: 15 May 2019
(This article belongs to the Special Issue The Molecular and Cellular Basis for Multiple Sclerosis)
PDF [499 KB, uploaded 15 May 2019]
  |     |  


Background: Glatiramer acetate (GA) is an effective treatment for the earliest stages of multiple sclerosis (MS)—clinically isolated syndrome (CIS) or clinically definite MS (CDMS). Objective: This study aims to determine the differences in the lymphocyte population (at baseline and the course of five years) between confirmed sustained progression (CSP) and non-CSP groups and to identify potential biomarkers among these parameters that can predict a positive response to the treatment. Methods: Twelve male and 60 female patients were included in the study. Peripheral blood samples were collected before and five years after treatment with GA. The authors compared lymphocyte parameters between the CSP and non-CSP groups by statistical analyses. Univariate and penalized logistic regression models were fitted to identify the best lymphocyte parameters at baseline and their combination for potential biomarkers. Subsequently, the ROC analysis was used to identify cut-offs for selected parameters. Results: The parameter CD4+/CD45RO+ was identified as the best single potential biomarker, demonstrating the ability to identify patients with CSP. Moreover, a combination of four lymphocyte parameters at baseline, relative lymphocyte counts, CD3+/CD69+, CD4+/CD45RO+, and CD4+/CD45RA+ab, was identified as a potential composite biomarker. This combination explains 23% of the variability in CSP, which is better than the best univariate parameter when compared to CD4+/CD45RO+ at baseline. Conclusions: The results suggest that other biomarkers can help monitor the conditions of patients and predict a favourable outcome. View Full-Text
Keywords: multiple sclerosis; glatiramer acetate; biomarker; CD4+/CD45RO+; patients; disease progression multiple sclerosis; glatiramer acetate; biomarker; CD4+/CD45RO+; patients; disease progression

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Vališ, M.; Sobíšek, L.; Vyšata, O.; Klímová, B.; Andrýs, C.; Vokurková, D.; Masopust, J.; Pavelek, Z. CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate. Cells 2019, 8, 456.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top